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1 We studied the effect of temperature on the binding to rat heart M2 muscarinic receptors of 
antagonists related to the carbon/silicon pairs pridinol/sila-pridinol and diphenidol/sila-diphenidol (in-
cluding three germanium compounds) and six structurally related pairs of enantiomers [(R)- and 
(S)-procyclidine, (R)- and (S)-trihexyphenidyl, (R)- and (S)-tricyclamol, (R)- and (S)-trihexyphenidyl 
methiodide, (R)- and (S)-hexahydro-diphenidol and (R)- and (S)-hexbutinol]. Binding affinities were 
determined in competition experiments using [3H]-N-methyl-scopolamine chloride as radioligand. The 
reference drugs were scopolamine and N-methyl-scopolamine bromide. 
2 The affinity of the antagonists either increased or decreased with temperature. van 't Hoff plots were 
linear in the 278-31OoK temperature range. Binding of all antagonists was entropy driven. Enthalpy 
changes varied from large negative values (down to - 29 kJ mol-I) to large positive values (up to 
+ 30 kJ mol-I). 
3 (R)-configurated drugs had a 10 to 100 fold greater affinity for M2 receptors than the corresponding 
(S)-enantiomers. Enthalpy and entropy changes of the respective enantiomers were different but no 
consistent pattern was observed. 
4 When silanols (R3SiOH) were compared to carbinols (R3COH), the affinity increase caused by CjSi 
exchange varied between 3 and 10 fold for achiral drugs but was negligible in the case of chiral drugs. 
Silanols induced more favourable enthalpy and less favourable entropy changes than the corresponding 
carbinols when binding. Organogermanium compounds (~Ge) when compared to their silicon counter-
parts (~Si) showed no significant difference in affinity as well as in enthalpy and entropy changes. 
5 Exchange of a cyclohexyl by a phenyl moiety was associated with an increase or a decrease in drug 
affinity (depending on the absolute configuration in the case of chiral drugs) and generally also with a 
more favourable enthalpy change and a less favourable entropy change of drug binding. 
6 Replacement of a pyrrolidino by a piperidino group and increasing the length of the alkylene chain 
bridging the amino group and the central carbon or silicon atom were associated with either an increase 
or a decrease of entropy and enthalpy changes of drug binding. However, there was no clear correlation 
between these structural variations and the thermodynamic effects. 
7 Taken together, these results suggest that hydrogen bond-forming OH groups and, to a lesser extent, 
polarizable phenyl groups contribute significantly to the thermodynamics of interactions between these 
classes of muscarinic antagonists and M2 muscarinic receptors. 
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Introduction 
As recently reviewed by Raffa & Porreca (1989) as well as by 
Hitzemann (1988), thermodynamic analysis of drug-receptor 
interactions is often used to obtain new information on the 
differences betweeg agonist and antagonist binding to their 
receptors. Interest in. the temperature-dependence of drug 
binding was initiated by a study of Weiland et al. (1979). 
These authors observed that agonist binding to turkey ery-
throcyte p-adrenoceptors is far more temperature-dependent 
than antagonist binding. They interpreted this observation as 
indication that the processes leading to information transfer 
(conformational change of the receptor, receptor-effector 
interaction, etc.) are driven by enthalpy changes. In contrast 
with these results, we and others (Barlow et al., 1979; Barlow 
& Burston, 1979; Waelbroeck et al., 1985; Gies et al., 1986; 
Muzio et al., 1986) did not observe any coherent pattern 
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when comparing agonist and antagonist binding to various 
muscarinic receptor subtypes: positive or negative enthalpy 
changes of binding were observed independently of the drugs' 
intrinsic efficacy. As explained below, we suspected that the 
great variation of AHo, and AS"' characterizing antagonist 
binding to cardiac M2 muscarinic receptors might reflect 
differences in the forces driving the drug-receptor interaction 
(Waelbroeck et al., 1985). 
Hoping to identify the contribution of such forces, we 
investigated in this work the effect of temperature on the 
binding to rat cardiac muscarinic M2 receptors of a family of 
muscarinic antagonists structurally related to the carbon/ 
silicon pairs pridinol/sila-pridinol and diphenidol/sila-di-
phenidol (see Figure I), including enantiomerically pure 
stereo isomers in the case of some chiral drugs. The selective 
binding and functional affinities of most of the drugs under 
investigation to M 1-M4 receptors have been published 
elsewhere (Eltze et al., 1988; Lambrecht et al., 1988; 1989a,b; 
Feifel et al., 1990; Dorje et al., 1991; Waelbroeck et al., 
1989a,b; 1990a,b; 199Ia,b; 1992). The results of functional 
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Figure I Chemical structure of the antagonists tested in this study (for drug names, see Tables I and 2). 
studies (Eltze et al., 1988; Lambrecht et aI., 1988; 1989a,b, 
and unpublished work; Wae1broeck et al., 1989b; Feifel et al., 
1990) showed that all ligands used were devoid of any 
agonist activity. The studies described here are related to our 
systematic investigations on carbon/silicon bioisosterism (for 
a recent review, see Tacke & Linoh, 1989). Scopolamine and 
N-methyl-scopolamine bromide were used as reference drugs. 
The compounds listed in Figure 1 were chosen to exem-
plify the chemical and physicochemical properties that might 
be of importance for enthalpy and entropy effects during 
drug-receptor interactions. Among the structural parameters 
were: absolute configuration, CjSi and Si/Ge exchange, 
cyclohexyl/phenyl exchange, variation in the amino group, 
variation of the side chain. 
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We chose to use a rat heart preparation for two reasons: 
(1) Rat heart contains only M2 receptors, one of the five 
subtypes of muscarinic receptors which have been described 
in mammalian tissues (Hulme et al., 1990; Dorje et al., 1991). 
(2) The association and dissociation rate constants of 
antagonists binding to M2 muscarinic receptors are greater 
than to other subtypes (M!> M3 or M4) (Waelbroeck et al., 
1986; 199Ic). It is therefore easier to achieve equilibrium 
binding in this system, especially at low temperatures. 
Binding affinities of antagonists were determined in competi-
tion experiments by the use of [3H]-N-methyl-scopolamine 
chloride ([3H]-NMS) as radioligand. 
Methods 
Cardiac homogenate preparation 
Male Wistar Kyoto rats (200-250 g) were killed by decapita-
tion, the heart immediately removed and rinsed in 150 mM 
NaCl. The homogenization buffer consisted of 20 mM Tris-
HCI (PH 7.5) enriched with 250 mM sucrose. Each heart was 
homogenized in 2 ml of this buffer with an Ultraturrax 
homogenizer (maximal speed, 5 s at 4°C) followed by the 
addition of 13 ml of the same buffer, and 7 up and down 
strokes in a glass-Teflon homogenizer at 4°C. The resulting 
homogenate was filtered on two layers of medical gauze and 
either used fresh or stored in liquid nitrogen until use (with 
no change of muscarinic binding properties). 
The protein concentration was determined according to 
Lowry et al. (1951) with bovine serum albumin as standard. 
The final protein concentration was 400 to 500 /lg protein per 
assay, corresponding to about 250 pM muscarinic binding 
sites. 
Binding assay 
[3H]-NMS binding was measured in a total volume of 1.2 ml, 
in a 50 mM sodium phosphate buffer (pH 7.4) enriched with 
2 mM MgCh. The incubation periods chosen were 4 h at 4°C, 
2 h at 12°C, I h at 25°C and 20 min at 37°C. PH]-NMS 
saturation curves were obtained with different tracer concen-
trations from 0.25 nM to 4.0 nM. The tracer concentration for 
competition experiments was 1.0 nM at all temperatures. 
To terminate the incubation, each sample was diluted with 
2 ml of ice-cold 50 mM sodium phosphate buffer (pH 7.4) 
and filtered on GF/C glass fibre filters (Whatman, Maid-
stone, England) presoaked in 0.05% polyethylenimine. The 
filters were rinsed three times with the same buffer, dried, and 
the radioactivity counted by liquid scintillation. 
Non-specific binding was defined as [3H]-NMS binding in 
the presence of I /lM atropine. 
Controls 
As reported in our previous study using cardiac membranes 
rather than homogenates (Waelbroeck et al., 1985), the total 
receptor concentration was not affected by temperature; the 
half-life of dissociation of the [3H]-NMS-receptor complex 
varied between approximately 20 min at YC and less than 
1 min at 37°C. The incubation times chosen in this study 
were well over 5 dissociation half-lives, and therefore 
sufficient to allow full equilibration of the binding reaction. 
The temperature varied by at most ± 1°C during the incuba-
tion. 
Mathematical analysis and statistics 
As found in our previous study (Waelbroeck et al., 1985) the 
PH]-NMS Scatchard plots (Scatchard, 1949) were linear at 
all temperatures studied. The average Ko values of [3H]-NMS 
were not significantly different from Ko values in our 
previous study, at the four temperatures used (Waelbroeck et 
al., 1985). 
The Hill coefficients of antagonist competition curves were 
not significantly different from 1.0, supporting the hypothesis 
that rat heart muscarinic receptors are homogeneous. Com-
petition curves were therefore analysed assuming the 
existence of a single receptor class, by use of a computer 
assisted curve fitting procedure (Richard son & Humrich, 
1984). ~ values were calculated from IC50 estimates using the 
Cheng & Prusoff (1973) equation. Affinity constants, as 
opposed to dissociation constants should be used to evaluate 
the enthalpy and entropy changes associated with binding; 
we therefore calculated the KA values as II Ki> the log KA 
value being in fact equal to pKi• All experiments were 
repeated 3 times at four temperatures. To estimate the values 
of the ~Ho, and ~So" we plotted the In KA values as a 
function of liT, T being the absolute incubation temperature 
(van 't Hoff plots). All results were compatible with linear 
van 't Hoff plots. The enthalpy change (~H"') due to the 
binding reaction was derived from the slope of this line, and 
the entropy change (~SO') from its ordinate intercept, as 
shown by the following equation: 
~Ho, ~So, 
+ 
R T R 
We obtained very low standard deviations for some of the 
IC50 values; however, we felt that this is an underestimate of 
the true error, when taking into account the different IC50 
value estimates obtained for a single drug in different batches 
of results (i.e. comparing four receptor subtypes rather than 
four temperatures). We therefore used the highest estimate of 
the standard deviation to evaluate the statistical significance 
of our results. 
The standard deviation of each IC50 value was below 16% 
of the average value in all cases, corresponding to a In KA 
standard deviation of about 0.16, and are not mentioned in 
the Tables. Due to the relatively small temperature range 
accessible to experiment (278 to 310° K), this corresponds to 
large standard deviation values for enthalpy and entropy 
changes: ± 5.51 kJ mol-' for ~H"' and ± 18.6 J mol-' K-' 
for ~So, (assuming no error in tracers Ko values used to 
calculate KA values). We used this standard deviation 
estimate to calculate the standard deviation of the slope and 
ordinate intercept of the van 't Hoff plot (proportional 
respectively to ~Ho, and ~SO'), as explained by Colquhoun 
(1971). Using these estimates, we considered the differences 
of ~Ho, and ~So, as statistically significant if they were, 
respectively, greater than 8.6 kJ mol-' and 29.8 J mol-' K-' 
(P>0.90); 11.0 kJ mol-' and 37.3Jmol-'K-' (P>0.95) or 
13.2kJmol-' and 44.7Jmol-'K-' (P>0.98). This is 
indicated in the tables as (*P>0.90), (**P>0.95) or 
(*** P> 0.98). 
Compounds 
Compounds were chosen to exemplify chemical and physico-
chemical properties which might determine the entropic and 
enthalpic effects of drug-receptor interactions. 
Absolute configuration Some of the drugs listed in Figure 1 
are chiral, containing a carbon, silicon or germanium atom 
as the center of chirality. We used the configurationally stable 
(R)- and (S)-enantiomers of the carbinols, R'R2R3COH, to 
assess the importance of absolute configuration for the 
enthalpy and entropy changes of binding. Most of these 
carbinols were also studied as racemates. Since we have 
indications that structurally analogous silanols, R'R2R3SiOH, 
may racemize in aqueous solution (Tacke et aI., 1987a) these 
drugs were only tested as racemates. The chiral (hydrox-
ymethyl)silanes, R'R2R3SiCH20H, and the chiral (hydrox-
ymethyl)germanes, R'R2R3GeCH20H, were also studied as 
racemates. 
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C/Si and Si/Ge exchange Carbon, silicon and germanium 
are members of Group IV of the Periodic Table. Carbon 
compounds RIR2R3R4C may differ from their sila-analogues, 
R1R2R3R4Si, and germa-analogues, R 1R2R3R4Ge, in several 
res~ts: (I) Due to the different covalent radii of carbon 
(0.77 A), silicon (1.l7 A) and germanium (1.22A), the 
analogues R 1R2R3R4El (El = C, Si, Ge) may differ in their 
surface (and thus in their lipophilicity) and in their 
conformational flexibility (C < Si < Ge); (2) Since carbon has 
a greater electronegativity than silicon and germanium 
(C>Si~Ge), the carbon compounds may differ somewhat 
from their sila- and germa-analogues in their bond polariza-
tions; (3) A special effect observed upon CjSi exchange (sila-
substitution) of tertiary carbinols R1R2R3COH is an increase 
in OH acidity. Thus the silanols R1R2R3SiOH are more 
acidic than the carbinols and may form stronger hydrogen 
bonds with electron donors (Tacke & Linoh, 1989). 
Generally, the chemical and physicochemical properties of 
silicon and germanium analogues are considerably closer to 
each other than to their carbon analogues (Lukevics & 
Ignatovich, 1992). 
Cyclohexyl/phenyl exchange The cyclohexyl and phenyl 
group differ only slightly in size, but the phenyl moiety is 
considerably more polarizable than the cyclohexyl group. 
Variation of the amino group Replacement of the pyr-
rolidino by a piperidino group as well as N-methylation leads 
to an increase in size. 
Variation of the side chain Elongation of the EI-CHzCHz-N 
chain (El = C, Si) by an additional methylene group (~El­
CHzCHzCHz-N) leads to an increase in size and conforma-
tional flexibility. 
Scopolamine hydrobromide and N-methyl-scopolamine 
bromide were obtained from Merck (Darmstadt, Germany). 
Racemic procyclidine hydrochloride (la.HCl) was provided 
by Deutsche Wellcome (Burgwedel, Germany). The (R)- and 
(S)-enantiomers of procyclidine [(R)- and (S)-1a] (Tacke et 
aI., 1986) as well as racemic sila-procyclidine (lb) (Tacke et 
al., 1983; 1987b) were synthesized according to the literature. 
Dicyclidine (2a) and sila-dicyclidine (2b) were obtained by 
catalytic hydrogenation of pyrrinol (3a), and sila-pyrrinol 
(3b), respectively (Tacke et aI., unpublished work). Pyrrinol 
(3a) (Adamson, 1949), sila-pyrrinol (3b) (Tacke et aI., 1984), 
racemic sila-trihexyphenidyl (4b) (Tacke et al., 1983; 1987b), 
pridinol (5a) (Adamson, 1949), sila-pridinol (5b) (Tacke et 
al., 1980; 1984), racemic hexahydro-diphenidol hydrochloride 
(6a.HCl) (Tacke et al., 1985), (R)- and (S)-hexahydro-
diphenidol hydrochloride [(R)- and (S)-6a.HCl] (Tacke et aI., 
1989a), and racemic hexahydro-sila-diphenidol hydrochloride 
(6b.HCl) (Tacke et al., 1987b) were also synthesized accord-
ing to published procedures. Racemic trihexyphenidyl hydro-
chloride (4a.HCl) was obtained from Sigma Chemical Co (St 
Louis, MO, U.S.A.), and (R)- and (S)-trihexyphenidyl hydro-
chloride [(R)- and (S)-4a.HCl] were a gift from Dr Aasen 
(Oslo, Norway). Dicyclidol hydrochloride (7.HCl) was 
obtained by analogy to the synthesis of (R)- and (S)-
hexahydro-diphenidol hydrochloride, starting from dicyclo-
hexyl ketone (Tacke et al., unpublished work). Diphenidol 
(8a) (Miescher & Marxer, 1946) and sila-diphenidol (8b) 
(Steiling et al., 1979; Tacke et al., 1979) were prepared ac-
cording to the literature. The racemic (hydroxymethyl)silane 
9a, the (hydroxymethyl)silane lOa, the racemic (hydroxy-
methyl)germane 9b and the (hydroxymethyl)germane lOb 
were prepared (as hydrochlorides) according to the reaction 
sequence outlined in the literature (Tacke et al., 1991) for the 
synthesis of 9a (starting materials: trichloro(chloromethyl) 
silane and trichloro(chloromethyl)germane, respectively (Tacke 
et al., unpublished work). (R)- and (S)-hexbutinol [(R)- and 
(S)-l1] (Tacke et al., 1989a) and (R)- and (S)-tricyclamol 
iodide [(R)- and (S)-12] (Tacke et al., 1986) were synthesized 
according to the literature. (R)- and (S)-trihexyphenidyl 
methiodide [(R)- and (S)-N-methyl-trihexyphenidyl iodide, 
(R)- and (S)-13] were gifts from Dr Aasen (Oslo, Norway). 
Sila-diphenidol methiodide (N-methyl-sila-diphenidol iodide, 
14) (Steiling et al., 1979) was synthesized according to the 
literature. The methiodides 15a and 15b were obtained by 
quaternization of the corresponding free bases lOa and lOb, 
respectively, with methyl iodide (Tacke et al., unpublished 
work). Racemic hexocyclium methyl sulphate (l6a) (Zaugg et 
al., 1958) and racemic sila-hexocyclium methyl sulphate (16b) 
(Tacke et al., 1989b) were synthesized according to the 
literature. 
PH]-NMS (1-[N-methyPH]-methyl-scopolamine chloride 
(74 Ci mmol- 1) was obtained from Amersham International 
(Bucks, England). Polyethylenimine was obtained from 
Sigma Chemicals Co (St Louis, MO, U.S.A.). All other 
chemicals were of the highest grade available and used as 
purchased. 
Results 
General remarks 
As previously observed for selective muscarinic antagonists 
(Waelbroeck et al., 1986; 1990b) the Hill coefficients of com-
petition curves were not significantly different from 1.0 and 
[3H]-NMS Scatchard plots were linear (not shown). This 
confirmed that rat heart muscarinic receptors were homo-
geneous (M2) receptors. The log KA values of the pridinol/ 
sila-pridinol and diphenidol/sila-diphenidol type drugs studied 
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Figure 2 van 't Holf plots of binding of procyclidine (la), sila-
procyclidine (lb), dicyclidine (2a), sila-dicyclidine (2b), pyrrinol (3a), 
and sila-pyrrinol (3b). The equilibrium association constants of pro-
cyclidine (la) (.), sila-procyclidine (lb) (0), dicyclidine (2a) (.), 
sila-dicyclidine (2b) (t.), pyrrinol (3a) (e), and sila-pyrrinol (3b) (0) 
were calculated as explained in Methods, at four temperatures. In 
(KA) was then plotted as a function of the reciprocal of the absolute 
temperature. Each point is the average of three determinations in 
duplicate. The lines were drawn with the aHo, and as·' values 
calculated as indicated in the Methods section. 
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here varied between 5.8 and 8.9, depending on the drug 
structure and, in the case of chiral compounds, on the 
absolute configuration (Tables I and 2). 
When the effects of temperature on the binding of 
unlabelled drugs were plotted according to van 't Hoff, linear 
plots were obtained suggesting that ~Ho, and ~So, were 
constant in the temperature-range studied. This is illustrated 
in Figure 2 for representative antagonists. ~Ho, and ~So, 
values obtained from these van 't Hoff plots are summarized 
in Table I (racemic and achiral drugs) and 2 (enan-
tiomerically pure chiral drugs). ~Ho, values varied between 
- 28.9 kJ mol-' (for scopolamine binding) to + 29.6 kJ 
mol-' [for (R)-6a]. ~So, values were all positive and varied 
between + 70 J mol-' K-' (scopolamine) and + 236 J mol-' 
K-' [(R)-6a). There was no correlation between the affinity of 
antagonists for cardiac M2 muscarinic receptors and the 
enthalpy or entropy changes due to drug-receptor interaction. 
We already know that sila-substitution affects differently 
the affinity of the (R)- and (S)-enantiomers of procycIidine 
[(R)- and (S)-la] for cardiac muscarinic receptors, and that 
silanol derivatives may racemize in aqueous solution (for 
functional studies with the enantiomers of sila-procycIidine 
[(R)- and (S)-lb] see: Tacke et al., 1987a). The values of ~Ho, 
and ~So, of binding of the enantiomers of chiral silanols are 
therefore difficult to evaluate with precision. Theoretically, if 
the (S)-enantiomers are unable to recognize muscarinic recep-
tors, the log KA values of racemic compounds should be 
underestimated by 0.3 log units [as compared to the active 
(R)-enantiomers] at all temperatures. Since ~Ho, measures 
the temperature dependence of In KA (slope of the van 't Hoff 
plot), the ~Ho, of the racemic compounds and of the corres-
ponding active (R)-enantiomer should be identical. By con-
trast, since all log KA values could be underestimated by 
0.3 log units, resulting in an error in the determination of the 
ordinate intercept of van 't Hoff plots, the ~So, of racemic 
drugs could be underestimated by R.ln2 = 5.8 J mol-' K-'. 
In fact, the log KA , ~Ho, and ~So, of binding of racemic 
procycIidine (la), trihexyphenidyl (4a) and hexahydro-
diphenidol (6a) were similar to the log K A , ~Ho, and ~So, 
obtained using their (R)-enantiomers (Tables I and 2) and we 
did not observe the expected differences of log KA and ~So,. 
This was probably due, in part, to the weak but significant 
binding affinity of (S)-enantiomers to cardiac muscarinic 
receptors: the stereoseIectivity of cardiac receptors for these 
drugs was 'only' 10 to 100 fold (Table 2), suggesting that the 
less potent enantiomer could participate in drug binding. 
By analogy with these results with carbinols (R3COH), we 
considered that the experimental ~H"' and ~So, of binding of 
analogous racemic silanols (R3SiOH) were reasonable 
estimates for the thermodynamic parameters of binding of 
their active (R)-enantiomers. 
Absolute configuration 
Comparison of the binding properties of the corresponding 
(R)- and (S)-enantiomers indicated that the enthalpy and 
entropy changes associated with drug binding (Table 2) could 
be markedly affected by the absolute configuration of the 
drugs. 
Effect of si/a-substitution 
SiIa-substitution increased the drug affinity for the receptor 
(Table 3), with the exception of the carbon/silicon pairs 
trihexyphenidyl/sila-trihexyphenidyl (4a/4b) , hexahydro-di-
phenidol/hexahydro-sila-diphenidol (6a/6b) and hexocyclium/ 
sila-hexocyclium (16a/16b). In all cases, CjSi exchange led to 
negative ~~Ho, and ~~So, values, significantly so for five out 
of eight pairs. 
Silicon/germanium exchange 
Substitution of the silicon by a germanium atom was 
associated with small non-significant decreases of the drugs' 
affinities and of ~H"' and ~So, values (Table 4). 
Table I Values of log KA data" at 25T and of the enthalpy and entropy changes associated with the binding of several racemic or 
achiral antagonists to rat cardiac (M2) muscarinic receptors, measured by van 't Hoff analysis 
Drugs Enthalpy changes Entropy changes 
No. Name log KA (I1W') (I1S·') 
(kJmol-') (Jmol-' K-') 
la Procyclidine 7.42 + 14.6 + 191 
lb Sila-procyclidine 7.72 - 5.8 + 128 
2a Dicyclidine 5.99 + 28.1 + 209 
2b Sila-dicyc1idine 6.98 + 9.5 + 166 
3a Pyrrinol 6.85 + 11.6 + 170 
3b Sila-pyrrinol 7.61 8.8 + 116 
4a Trihexyphenidyl 7.86 + 8.9 + 180 
4b Sila-trihexyphenidyl 7.61 + 2.8 + 155 
5a Pridinol 7.50 + 3.9 + 156 
5b Sila-pridinol 7.76 4.7 + 130 
6a Hexahydro-diphenidol 6.85 + 26.8 + 222 
6b Hexahydro-sila- 6.68 + 10.0 + 162 
diphenidol 
7 Dicyclidol 6.06 + 22.5 + 193 
8a Diphenidol 6.42 + 15.2 + 175 
8b Sila-diphenidol 7.01 4.8 + 118 
9a 6.81 + 9.7 + 164 
9b 6.31 + 7.5 + 148 
lOa 6.16 + 8.1 + 146 
lOb 6.12 + 4.9 + 133 
14 N-methyl-sila- 8.01 - 19.1 + 90 
diphenidol iodide 
15a 6.78 - 9.5 + 98 
15b 6.73 - 12.4 + 87 
16a Hexocyclium methyl 7.61 + 3.0 + 154 
sulphate 
16b Sila-hexocyclium 7.50 4.0 + 130 
methyl sulphate 
"The standard deviation of log KA was about 0.10 and the standard deviation of the estimates of I1W' and I1S·' 
approximately ± 5.51 kJ mol-' and ± 18.6 J mol-' K-', respectively (see text: Mathematical analysis and statistics). 
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Table 2 Values of log KA at 25'C and of the enthalpy and entropy changes associated with the binding of the (R)- and 
(8)-enantiomers of several antagonists to rat cardiac (M2) muscarinic receptors, measured by van 't Hoff analysis" 
Drugs Enthalpy changes Entropy changes 
No. Name log KA (aH") (as") 
(kJmol- l ) (Jmol- I K- I) 
(R)-la (R)-Procyc1idine 7.58 + 13.6 + 190 
(8)-la (8)-Procyc1idine 5.76 + 18.5 + 172 
(R)-4a (R)-Trihexyphenidyl 7.81 + 8.5 + 178 
(8)-4a (8)-Trihexyphenidyl 6.01 + 13.8 + 162 
(R)-6a (R)-Hexahydro-diphenidol 7.08 + 29.6 + 236 
(8)-6a (8)-Hexahydro-diphenidol 5.81 + 21.4 + 183*** 
(R)-l1 (R)-Hexbutinol 7.98 - 5.4 + 134 
(8)-11 (8)-Hexbutinol 7.15 + 23.8*** + 217*** 
(R)-12 (R)-Tricyc1amol iodide 8.38 + 18.2 +221 
(8)-12 (8)-Tricyc1amol iodide 6.61 + 12.1 + 167*** 
(R)-13 (R)-N-methyl-trihexyphenidyl 8.92 + 14.3 + 218 
iodide 
(8)-13 (8)-N-methyl-trihexyphenidyl 6.98 + 7.7 + 159*** 
iodide 
Scopolamine 8.76 - 28.9 + 70 
N-methyl-scopolamine bromide 9.53 - 26.9 + 92 
"The standard deviation of log KA was about 0.10 and the standard deviation of the estimates of aH" and as" 
approximately ± 5.51 kJ mol-I and ± 18.6 J mol-I K- I , respectively (see text: Mathematical analysis and statistics). 
***Significantly different (P>0.98) from entropy (enthalpy) change associated with binding of the (R)-enantiomer. 
Table 3 Differences between the log KA , aH" and as" values observed when comparing the binding of structurally analogous 
carbinols and silanols (C/Si exchange, si la-substitution) 
Drugs 
Procyc1idine (1a)/ 
Sila-procyc1idine (1b) 
Dicyc1idine (2a)/ 
Sila-dicyc1idine (2b) 
Pyrrinol (3a)/Sila-pyrrinol (3b) 
Trihexyphenidyl (4a)/ 
Sila-trihexyphenidyl (4b) 
Pridinol (5a)/Sila-pridinol (5b) 
Hexahydro-diphenidol (6a)/ 
Hexahydro-sila-diphenidol (6b) 
Diphenidol (8a)/Sila-diphenidol (8b) 
Hexocyclium methyl sulphate (16a)/ 
Sila-hexocyc1ium methyl sulphate (16b) 
Statistically significant: *P>0.90; **P>0.95; ***P>0.98. 
Table 4 Differences in log KA , aH" and as" values 
observed when comparing the binding of structurally 
analogous silanes and germanes (Si/Ge exchange) 
Drugs a log KA aaH" aas" 
(kJ mol-I) (J mol-I K- I ) 
9a/9b - 0.50 - 2.2 - 16 
lOa/lOb - 0.04 - 3.2 -13 
15a/15b - 0.05 - 2.9 -11 
Cyclohexyljphenyl exchange 
Substitution of a cyc10hexyl by a phenyl group increased or 
decreased the drug affinities, depending on the absolute 
configuration of the chiral compounds (Table 5). Except for 
the pair dicyc1idol/{R)-hexahydro-diphenidol [7/{R)-6a], neg-
ative AAH" values were observed when replacing the cyc1o-
hexyl by a phenyl moiety, significantly so in eight out of 
nineteen pairs of molecules. This was compensated by less 
a log KA aMI" aas' 
(kJ mol-I) (J mol-I K- I ) 
+ 0.30 - 20.4*** - 63*** 
+ 0.99 - 18.6*** - 43** 
+ 0.76 - 20.4*** - 54*** 
- 0.25 - 6.1 - 25 
+ 0.26 8.6* -26 
- 0.17 - 16.8*** - 60*** 
+ 0.59 - 20.0* - 57*** 
- 0.11 - 7.0 -24 
favourable entropic effects (negative AAS" values), statis-
tically significant in seven out of nineteen pairs of drugs. 
N-methylation of the cyclic amino group 
The effect of N-methylation on log KA , AH" and AS" values 
of (R)- and {S)-procyc1idine [(R)- and {S)-la], (R)- and (S)-
trihexyphenidyl [(R)- and {S)-4a] , sila-diphenidol [8b], lOa 
and lOb, is summarized in Table 6. The log KA values were 
increased by up to one log unit, depending on the drugs' 
structure. The modifications of AH" and AS" were positive 
with the {R)-enantiomers, negative with the {S)-enantiomers 
and achiral compounds. 
Pyrrolidino j piperidino exchange 
Only small and non-significant modifications (of either sign) 
of the compounds' affinities, and of the AH" and AS" values 
of binding were observed (Table 7). 
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Table 5 Differences in log KA , ,6,H" and ,6,so, values observed when comparing the binding of compounds with a cyclohexyl group 
and their corresponding phenyl analogues (cyclohexyl/phenyl exchange) 
Drugs ,6, log KA ,6,,6,Ho, ,6,,6,so, 
1 Cyclohexyl/phenyl group (kJmol-') (Jmol-' K-') 
(R)-Procyclidine [(R)-l a]/Pyrrinol (3a) - 0.73 - 2.0 -20 
(8)-Procyclidine [(8)-la]/Pyrrinol (3a) + 1.09 - 6.9 - 2 
Sila-procyclidine (1b)/ _ 0.11" - 3.0 -12 
Sila-pyrrinol (3b) 
Dicyclidine (2a)/ + 1.59 - 14.5*** -19 
(R)-Procyclidine [(R)-la] 
Dicyclidine (2a)/ - 0.23 - 9.6* - 37* 
(8)-Procyclidine [(8)-la] 
Sila-dicyclidine (2b)/ +0.74 - 15.3*** - 38* 
Sila-procyclidine (1b) 
(R)-Trihexyphenidyl [(R)-4a]/Pridinol (5a) -0.31 
- 4.6 - 22 
(8)-Trihexyphenidyl [(8)-4a]/Pridinol (5a) + 1.49 - 9.9* - 6 
Sila-trihexyphenidyl (4b)/ + 0.15" - 7.5 - 25 
Sila-pridinol (5b) 
(R)-Hexahydro-diphenidol [(R)-6a]/ -0.66 - 14.4* -61*** 
Diphenidol (8a) 
(8)-Hexahydro-diphenidol [(8)-6a]/ +0.61 - 6.2 - 8 
Diphenidol (8a) 
Hexahydro-sila-diphenidol (6b)/ + 0.33" - 14.8*** -44** 
Sila-diphenidol (8b) 
DicycIidol (7)/ + 1.02 + 7.1 +43** 
(R)-Hexahydro-diphenidol [(R)-6a] 
Dicyclidol (7)/ - 0.25 - 1.1 -10 
(8)-Hexahydro-diphenidol [(8)-6a] 
9a/1Oa - 0.65" - 1.6 - 18 
9b/lOb - 0.19" 2.6 -15 
2 Cyclohexyl/phenyl groups 
DicycIidine (2a)/Pyrrinol (3a) + 0.86 - 16.5** - 39* 
SiIa-dicyclidine (2b)/ + 0.63 - 18.3** - 50*** 
Sila-pyrrinol (3b) 
Dicyclidol (7)/Diphenidol (8a) + 0.36 - 7.3 -18 
'One drug in each pair is a racemic mixture, the second an achiral molecule. The differences in log KA , ,6,Ho, and ,6,so, shown in this 
Table are, therefore, approximate values only (see Results: general remarks). 
Statistically significant: * P> 0.90; ** P> 0.95; *** P> 0.98. 
Table 6 Differences in log KA, ,6,Ho, and ,6,so, values observed when comparing the binding of tertiary and the corresponding 
quaternary (N-methylated) drugs (N-methylation) 
Drugs ,6, log KA ,6,,6,Ho, ,6,,6,so, 
(R)-Procyclidine [(R)-la]/ 
(R)-TricycIamol iodide [(R)-12] 
(8)-ProcycIidine [(8)-la]/ 
(8)-Tricyclamo1 iodide [(8)-12] 
(R)-Trihexyphenidyl [(R)-4a]/ 
(R)-N-methyl-trihexyphenidyl 
iodide [(R)-13] 
(8)-Trihexyphenidyl [(8)-4a]/ 
(8)-N-methyl-trihexyphenidyl 
iodide [(8)-13] 
Sila-diphenidol (8b)/ 
N-methyl-sila-diphenidol iodide (14) 
10a/15a 
10b/15b 
Statistically significant: *P>0.90; **P>0.95; ***P> 0.98. 
Side-chain elongation 
Elongation of the El-CH2CHr N side chain (El = C,Si) by an 
additional methylene group led to a decrease by up to one 
log unit of log KA values (Table 8). Except for the pair 
(kJ mol-') (J mol-' K-') 
+0.80 + 4.6 + 31* 
+0.85 - 6.4 - 5 
+ 1.11 + 5.8 +40** 
+0.97 - 6.1 - 3 
+1.00 - 14.3*** - 28 
+ 0.62 -17.6*** -48*** 
+0.61 - 17.3*** - 46*** 
(R)-trihexyphenidyl/(R)-hexahydro-diphenidol [(R)-4a/(R)-6a] 
(statistically significant increases of the .1Ho, and .1so, values 
were found), only small and non-significant changes of either 
sign of .1Ho, and .1so, values were observed. 
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Table 7 Differences in log KA , aH·' and as·' values observed when comparing the binding of pyrrolidino-substituted compounds and 
their corresponding piperidino analogues (pyrrolidino/piperidino exchange) 
Drugs a log KA aaW' MS·' 
(kJ mol-') (J mol-' K-') 
(R)-Procyclidine [(R)-la]1 + 0.23 - 5.1 - 12 
(R)-Trihexyphenidyl [(R)-4a] 
(8)-Procyclidine [(8)-la)1 + 0.25 -4.7 - 10 
(8)-Trihexyphenidyl [(8)-4a) 
Sila-procyclidine (lb)1 - 0.11 + 8.6 + 27 
Sila-trihexyphenidyl (4b) 
Pyrrinol (3a)/Pridinol (5a) + 0.65 -7.7 -14 
Sila-pyrrinol (3b)1 + 0.15 +4.1 + 14 
Sila-pridinol (5b) 
(R)-Tricyclamol iodide [(R)-12)1 + 0.54 - 3.9 - 3 
(R)-N-methyl-trihexyphenidyl 
iodide [(R)-13) 
(8)-Tricyclamol iodide [(8)-12)1 + 0.37 - 4.4 - 8 
(8)-N-methyl-trihexyphenidyl 
iodide [(8)-13) 
Table 8 Differences in log KA , aH·' and as·' values observed when comparing the binding of compounds with an EI-CH2CHT N 
chain (El = C, Si) and their corresponding analogues containing an EI-CH2CH2CHT N moiety (elongation of the side chain) 
Drugs a log KA aaH·' aaS·' 
(R)-Trihexyphenidyl [(R)-4a)1 
(R)-Hexahydro-diphenidol [(R)-6a) 
(8)-Trihexyphenidyl [(8)-4a)1 
(8)-Hexahydro-diphenidol [(8)-6a] 
Sila-trihexyphenidyl (4b)1 
Hexahydro-sila-diphenidol (6b) 
Pridinol (5a)1 
Diphenidol (8a) 
Sila-pridinol (5b)1 
Sila-diphenidol (8b) 
Statistically significant: *** P> 0.98. 
Discussion 
The pioneering work of Weiland et al. (1979) on p-
adrenoceptors led to the hope that agonists and antagonists 
would generally induce different enthalpy and entropy 
changes when associating with their receptors (independently 
of the drug structure or of the receptor studied), so that these 
differences could reflect the initiation or blockade of inform-
ation transfer. Subsequent studies however indicated that this 
generalization was not tenable (Raffa & Porreca, 1989). 
Several authors therefore suggested that thermodynamic 
parameters of binding might reflect detailed molecular drug-
receptor interactions (Kilpatrick et al., 1986; Hitzemann, 
1988; Miklavc et al., 1990). 
In an attempt to understand the entha1pic and entropic 
effects of non-covalent binding, the thermodynamic behaviour 
of simple model systems has been investigated in great detail 
(Edelhoch & Osborne, 1976). The forces driving the non-
covalent association of two molecules are limited in number 
(Barrow, 1973; Ross & Subramanian, 1981). 
(1) Ionic bonds are formed when two groups with 
opposite charges are brought into close contact. Since free 
ions interact strongly with water (ion-dipole interactions), the 
entropy changes associated with ionic bond formation in 
aqueous solutions are positive (Edelhoch & Osborne, 1976; 
Ross & Subramanian, 1981). The enthalpy changes are small 
(Ross & Subramanian, 1981) or positive (Edelhoch & 
Osborne, 1976). The molecular rearrangement of water being 
strongly temperature-dependent, the heat capacity change 
(dCP"', variation of dH"' with temperature) associated with 
(kJ mol-') (J mol-' K-') 
- 0.73 +21.1*** + 58*** 
- 0.20 + 7.6 + 21 
- 0.93 + 7.2 + 7 
- 1.08 + 1l.3 + 19 
- 0.75 - 0.1 -12 
ionic bond formation is positive at 2S·C (Ede1hoch & 
Osborne, 1976). 
(2) van der Waals interactions cover all dipole-dipole 
attractions. They can be divided into three contributions: (2a) 
a dipole-dipole attraction term (attraction between two 
molecules with a permanent dipole); (2b) an induction effect 
(caused by polarization of the electrons of a molecule when 
brought into contact with a permanent dipole); and (2c) 
London dispersion forces, which describe the induction effect of 
each 'instantaneous' dipole on the adjacent polarizable atom or 
molecule, allowing induced dipole-induced dipole interactions 
regardless of whether the interacting atoms or molecules have a 
permanent dipole or not (Barrow, 1973). In aqueous solution, 
these interactions are associated with negative enthalpy and 
entropy changes (Edelhoch & Osborne, 1976). 
(3) Hydrogen binding occurs when a somewhat acidic 
hydrogen atom (carrying a partial positive charge) comes 
into contact with a lone electron pair of an atom, such as an 
oxygen or nitrogen atom, in a neighbouring molecule (Bar-
row, 1973). In aqueous solution, these interactions are also 
associated with negative enthalpy and entropy changes (Edel-
hoch & Osborne, 1976). Hydrogen bond formation, like 
hydrophobic interactions, is associated with a negative dCp·'. 
(4) Hydrophobic interactions appear when non-polar com-
pounds are brought into contact from water. These binding 
interactions result from the molecular rearrangement of 
water, and are therefore strongly temperature-dependent. 
They are associated with positive enthalpy and entropy 
changes and (by contrast with ionic bond formation) negative 
heat capacity changes (Edelhoch & Os borne, 1976). 
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Our goal in this work was to test the hypothesis that 
differences in enthalpy and entropy changes, associated with 
antagonist binding to cardiac muscarinic M2 receptors, could 
be explained by differences in hydrogen bonding or van der 
Waals interactions between the drug and its receptor. We 
therefore deliberately chose drugs with very similar chemical 
structures. Essential contributions to the solution of this 
problem was expected from the study of C/Si and Si/Ge 
pairs. 
Binding of the muscarinic antagonists studied was driven 
by a large entropy increase, while the enthalpy change 
associated with binding varied between large positive values 
and large negative values (this work, Tables 1 and 2; see also 
Barlow et al., 1979; Barlow & Burston, 1979; Waelbroeck et 
al., 1985; Gies et al., 1986; Muzio et al., 1986). Few of the 
differences of AH·' and AS·' of binding (AAH·' and AAS·') 
observed in this work could be considered as statistically 
significant, due to the small temperature range accessible to 
experiment (5 to 37·C), and to the small structural variations 
studied. Nevertheless, we believe that the results of our 
thermodynamic analysis provides an insight into the mole-
cular events underlying the interaction of antagonists with 
muscarinic receptors not obtainable by other experimental 
techniques. The following conclusions may be drawn: 
(1) We did not observe any variation of values of AH·' 
and AS·' of binding with temperature. It is known that the 
cationic head of quaternary ammonium or protonated amino 
groups of muscarinic antagonists interacts with a negatively 
charged aspartate residue (Hulme et al., 1990). This residue 
turns towards a relatively hydrophobic region of the recep-
tor, formed by a bundle of seven transmembrane helices 
(Hulme et al., 1990). Our results therefore suggest that the 
heat capacity changes due to hydrophobic, hydrogen, and 
ionic bond formation approximately compensated each other 
when the muscarinic antagonist binds to the receptor. 
(2) The entropy and enthalpy changes associated with 
binding of the corresponding (R)- and (S)-enantiomers were 
often significantly different (Table 2). This is a reminder that 
these drugs interact with an asymmetric binding site: thermo-
dynamic parameters reflect the drug-receptor interaction, not 
the drugs' chemical and physicochemical properties. The 
differences of affinity of the two enantiomers were below 100 
fold for the compounds studied here. This corresponds either 
to a AAH·' value of 10.6 kJ mol- 1 (assuming that the binding 
AS·' of the two enantiomers are equal) or to a AAS·' value of 
38 J mol- 1 K- 1 (assuming that the binding AH·' of the two 
enantiomers are equal). These values would be barely 
significant. For compounds (S)-la and (S)-4a, the binding 
AH·' and AS·' were both less favourable than those of (R)-1a 
or (R)-4a respectively: the AAH·' and AAS·' values were not 
statistically significant. In contrast, for the pairs of enan-
tiomers of 6a, 11, 12 and 13, the weaker (S)-enantiomer had 
either a more favourable AH·' or a more favourable AS·' as 
compared to the more potent (R)-enantiomer. This was over-
compensated by a very large unfavourable change of AS·' or 
AH·', respectively. 
(3) The enthalpy changes associated with binding of 
silanols (R3SiOH) were more favourable than those assoc-
iated with binding of the corresponding carbinols (R3COH) 
(Table 3). On the other hand, sila-substitution resulted in less 
favourable en tropic effects. This is in keeping with model 
systems (Edelhoch & Osborne, 1976; Ross & Subramanian, 
1981): silanols are more acidic than carbinols and therefore 
susceptible to form stronger hydrogen bonds either with an 
electron donor atom of the receptor or with water, and 
hydrogen bond formation is associated with negative en-
thalpy and entropy changes. 
(4) Since (hydroxymethyl)silanes (R3SiCH20H) and (hyd-
roxymethyl)germanes (R3GeCH20H) do not differ signi-
ficantly in OH acidity, Iipophilicity and conformational 
flexibility, Si/Ge exchange did not lead to the thermo-
dynamic effects observed upon C/Si exchange in the carbinol/ 
silanol (R3COH/R3SiOH) structures (compare Tables 4 and 
3). Generally, in accordance with the covalent radii 
(C«Si <Ge) and electronegativities (C<Si~Ge) of car-
bon, silicon and germanium, analogous silicon and ger-
manium compounds are considerably closer by their chemical 
and physicochemical properties than to their corresponding 
carbon analogues (Lukevics & Ignatovich, 1992). These 
similarities in their chemical and physicochemical properties 
are reflected by the distinct bioisosteric relationships between 
analogous silicon and germanium compounds (see for exam-
ple: Tacke et al., 1992). 
(5) The enthalpy change associated with binding of 
phenyl-substituted drugs was systematically more favourable 
than that of the corresponding cyclohexyl derivatives (Table 
5). This was in keeping with results expected from model 
systems (Edelhoch & Osborne, 1976; Ross & Subramanian, 
1981): a phenyl ring is more polarizable than a cyclohexyl 
group so that the contribution to van der Waals interactions 
via induction effects and London dispersion forces should be 
strengthened by substituting a cyclohexyl by a phenyl group. 
(6) N-methylation of the tertiary amino group, as well as 
increasing the size of the heterocycle from pyrrolidino to 
piperidino, or lengthening the alkylene chain (i.e. changes 
increasing the hydrophobicity and conformational flexibility 
of the drugs) did not change the thermodynamic parameters 
of drug binding in a clear way (compare Tables 6, 7, 8). This 
is in keeping with model systems (Edelhoch & Osborne, 
1976): dissolving hydrophobic molecules in water or their 
transfer from organic solvents into water (these reactions 
being equivalent to drug dissociation from the receptor) is 
associated with negative AH·' and AS·'values, but there is no 
correlation between the absolute value of AH·' and AS·' and 
the size of the hydrophobic molecule (Edelhoch & Osborne, 
1976). 
Although not extensive, the list of studies which have 
applied thermodynamic analysis to pharmacological data is 
growing (Raffa & Porreca, 1989). The data obtained for 
various receptors demonstrate that there is a wide diversity in 
the thermodynamic profiles for agonist and antagonist 
Iigands. For some receptors, such as the p-adrenoceptors, 
several reports are available (Raffa & Porreca, 1989). 
As stated in the Introduction, binding of p-adrenoceptor 
agonists is driven by a large enthalpy decrease, while 
antagonist binding is associated with an entropy increase 
(Weiland et al., 1979). This was interpreted as reflecting the 
receptor activation and interaction with a GTP-binding pro-
tein when an agonist is present. 
More recently, Strader et al. (1989) identified two serine 
residues which are involved in agonist activation of the P-
adrenoceptor. Agonist interaction with the receptor probably 
involves the formation of specific hydrogen bonds with these 
serine residues, causing the conformational changes in the 
receptor which lead to the activation of the GTP-binding 
protein. Since hydrogen bond formation is associated with 
the negative enthalpy and entropy changes, hydrogen bonds 
formation between the receptor and agonists but not between 
the receptor and antagonists might explain the observation 
that agonists but not antagonists binding to p-adrenoceptors 
is enthalpy driven. 
Thus, thermodynamic analysis of pharmacological data 
potentially offers an insight into the molecular events under-
lying drug-receptor interactions not obtainable by other tech-
niques. It offers the promise of measuring parameters that 
are more fundamental than equilibrium affinity constants. 
Implicit in thermodynamic analysis is quantitative measure-
ment of the driving forces involved in the drug-receptor 
interaction and responsible for the affinity of an antagonist 
for a receptor and the efficacy of an agonist. 
In conclusion, the thermodynamic analysis of the inter-
actions of several muscarinic antagonists of the pridinol, 
sila-pridinol, diphenidol and sila-diphenidol type with M2 
cardiac receptors suggests that hydrogen bonds and polar-
izable groups play an important role in determining the 
enthalpy and entropy changes associated with ligand binding. 
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The sila-substitution approach (C/Si exchange) proved to be 
a valuable tool in these studies. 
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